IL17A and myeloid sarcoma: Recent evidence also suggests that IL-17A has minimal capacity to activate microglia.23 CXCL9 is also reported to be increased in CSF in relapsing MS, and decreases in conjunction with response to certain treatments, such as natalizumab.24